Mitochondrial Transplant Reversed Cardiac Aging in Mice: Scientists Found the Molecular Switch That Triggers It
Mitochondrial Transplant Reversed Cardiac Aging in Mice: Scientists Found the Molecular Switch That Triggers It
Biologists at Shanxi Medical University in China discovered why clearance of damaged mitochondria breaks down in the aging heart and which protein drives that breakdown. Transplanting healthy mitochondria restored energy to mouse cardiac cells, silenced the protein, and brought the heart's pumping function back to near-normal levels. The results were published on September 23, 2026, in Aging Cell.
Mitochondria, the structures that produce nearly all of a cell's energy, age quickly, while cardiac cells barely renew over a lifetime. The cell dismantles a damaged mitochondrion through mitophagy: it tags the organelle and routes it for recycling inside a membrane vesicle. Naturally aged mice are scarce for experiments of this kind, so the team used doxorubicin, a chemotherapy drug whose cardiac side effects mimic aging. In these mice the clearance machinery does not shut down but becomes overwhelmed, with several-fold more tags and undigested vesicles than in young animals. Chloroquine, which blocks recycling at the final step, slowed it further still in young cells but had no additional effect in aged ones.
The culprit turned out to be the receptor BNIP3, not the better-known clearance pathway involving Parkin, whose activity did not differ between old and young cells. The gene driving BNIP3 overexpression was found by screening age-related regulators: it proved to be HIF-3α, a protein in the HIF family that governs how cells sense oxygen deprivation (the 2019 Nobel Prize in Physiology or Medicine was awarded for the discovery of this mechanism). HIF-3α was previously regarded as a transcriptional repressor, but in the aging heart it is the full-length isoform, not the truncated one, that is active. This isoform carries an activation domain rather than a silencing one; it binds to BNIP3 and drives its expression several-fold above normal.
To test causality, the authors artificially raised BNIP3 expression in healthy cardiac cells, and the cells aged without any chemical insult. When transplantation was accompanied by forced BNIP3 activation, the therapeutic effect disappeared. The same protein can both age a healthy cell and block treatment of an aged one.
The entire cascade begins with a shortfall in cellular fuel. An artificial drop in ATP, the cell's primary energy currency, was sufficient on its own to raise HIF-3α, even without signs of aging.
Mitochondrial transplantation worked in the opposite direction: it raised ATP and lowered HIF-3α together with BNIP3. Donor mitochondria were isolated from bone marrow mesenchymal stem cells, a source that is easier to scale, and delivered intravenously to mice with damaged hearts; the organelles integrated into cardiac tissue. Left ventricular ejection fraction, the share of blood the heart pushes out with each contraction, rose on average from 40%, typical of heart failure, to 55 to 58%, close to the healthy norm. At the same time, markers of cellular senescence and oxidative stress in cardiac mitochondria declined.
Confusing the effect of doxorubicin with aging itself is an easy mistake: Immorta Bio fell into this trap earlier, calling the survival of mice after a dose of the drug "life extension". To avoid repeating this error, the authors checked the same switch in naturally aged mice (eighteen months, a substantial age for a mouse) and in data from human cardiac cells: HIF-3α and BNIP3 both increased with age in the absence of chemotherapy.
Mitochondrial transplantation has already been tried in humans: in 2015, cardiac surgeons at Boston Children's Hospital were the first to inject mitochondria from the infants' own muscle directly into the heart after major surgery. In eight of twelve cases, this restored cardiac function. Intravenous transplantation of donor mitochondria into humans has not yet been attempted.